News Release
Takeda Announces Positive Interim Safety and Immunogenicity Data from its Phase 1/2
Study of Moderna’s COVID-19 Vaccine Candidate (TAK-919) in Japan−−Interim Results Indicate Immune Response Consistent With Clinical Study Data Previously
Reported by Moderna
Results Were Submitted to the Japan Pharmaceuticals and Medical Devices Agency to Support
Review of the Company’s New Drug Application to Import and Distribute the Vaccine Candidatein Japan

Osaka, Japan, May 10, 2021 -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today
announced positive interim results from the ongoing Phase 1/2 immunogenicity and safety clinical trial ofModerna’s mRNA COVID-19 vaccine candidate (TAK-919) in Japan have been submitted to the Japan
Pharmaceuticals and Medical Devices Agency (PMDA). Takeda currently has a three-way agreement with
Moderna and the Government of Japan’s Ministry of Health Labour and Welfare (MHLW) to import anddistribute 50 million doses of TAK-919 in Japan, pending regulatory approval.
This interim analysis showed binding antibody and neutralizing antibody titres were elevated at 28 days
after the second dose in 100% of people vaccinated with two 0.5ml doses of TAK-919 given 28 days apart.
The vaccine candidate was generally well-tolerated with no significant safety concerns reported.
“These data reinforce previously reported findings from Moderna clinical trials and suggest the potential
for this vaccine candidate to protect the Japanese population from COVID-19,” said Masayuki Imagawa,Head of Japan Vaccine Business Unit, Takeda. “Moderna’s COVID-19 vaccine is already being used incountries around the world, and we embrace the opportunity to work with regulatory authorities to bring
options that are proven safe and effective to the people of Japan. Every approved COVID-19 vaccine brings
us closer to ending the pandemic and providing a safer and healthier world for all.”
The study results were submitted to the Japan Pharmaceuticals and Medical Devices Agency (PMDA) tobe evaluated as part of the New Drug Application submitted in March 2021, which also includes safety andefficacy results from Moderna’s pivotal Phase 3 COVE trial conducted in the U.S. Takeda aims to begin
distribution of TAK-919 immediately following regulatory approval, should it be granted.
Takeda’s efforts to bring Moderna’s and Novavax’ vaccine candidates to Japan are supported by the MHLW
and the Japan Agency for Medical Research and Development (AMED).

1TAK-919 Clinical Trial
Takeda is conducting a placebo-controlled Phase 1/2 study in Japan to evaluate the safety andimmunogenicity of two vaccinations of TAK-919 given 28 days apart. Takeda has enrolled 200 participants
aged 20 years and older. Each participant was assigned to receive a placebo or a 0.5 ml dose of TAK-919
at both vaccinations. Participants will be followed for 12 months after the second vaccination.
The ClinicalTrials.gov identifier for this trial is NCT04677660.
About Takeda’s COVID-19 Efforts
Takeda is taking a comprehensive approach to treat and prevent COVID-19 today, and future pandemics
through multiple activities and partnerships including, but not limited to:•••Hyperimmune globulin: Takeda co-founded the CoVIg-19 Plasma Alliance and joined forces
with other leading plasma companies to evaluate a hyperimmune globulin medicine in a global
clinical trial. While the data did not meet its endpoints, the program has contributed to the scientificunderstanding of antibody-based treatment to address the virus and highlighted the broader
therapeutic value and importance of plasma to treat rare diseases.
Additional therapeutics: The company is assessing existing Takeda products for activity against
the COVID-19 virus and co-founded the COVID R&D Alliance. In addition, Takeda has
joined the Innovative Medicines Initiative (IMI) CARE consortium, the Accelerating
COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership and the COVID REDproject.
Vaccines: Takeda has partnered with the Government of Japan, Novavax and Moderna, to help
accelerate the availability of a COVID-19 vaccine. We are leveraging our extensive and wellestablished global manufacturing and supply capabilities and building upon our existing influenza
pandemic preparedness efforts in Japan. Takeda also announced a mutual agreement with IDT
Biologika GmbH (IDT) to utilize capacity at IDT for three months previously reserved for Takeda’s
dengue vaccine candidate to manufacture the single-shot COVID-19 vaccine developed by Janssen
Pharmaceutical Companies of Johnson & Johnson. Takeda supports our partners and alliances in ashared goal to rapidly discover, develop and deliver effective treatments and vaccines for COVID19 and ensure preparedness for future pandemics.

Takeda’s Commitment to Vaccines
Vaccines prevent 2 to 3 million deaths each year and have transformed global public health. For the past
70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global
vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases,
such as dengue, COVID-19, Zika and norovirus. Takeda’s team brings an outstanding track record and awealth of knowledge in vaccine development, manufacturing and global access to advance a pipeline ofvaccines to address some of the world’s most pressing public health needs. For more information, visit
www.TakedaVaccines.com.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven
biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming
treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D
efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, andGastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies andVaccines. We are focusing on developing highly innovative medicines that contribute to making adifference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced
collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are2committed to improving quality of life for patients and to working with our partners in health care inapproximately 80 countries. For more information, visit https://www.takeda.com.
Media Contacts:
Japanese Media:
Ryoko Matsumoto
ryoko.matsumoto@takeda.com+81 (0) 3-3278-3414
Media Outside Japan
Catherine Wilson
catherine.wilson@takeda.com+1 440-488-6242
Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question
and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical
Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and anyquestion-and-answer in connection with it) is not intended to, and does not constitute, represent or form
part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for,exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any
jurisdiction. No shares or other securities are being offered to the public by means of this press release. No
offering of securities shall be made in the United States except pursuant to registration under the U.S.
Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (togetherwith any further information which may be provided to the recipient) on the condition that it is for use by
the recipient for information purposes only (and not for the evaluation of any investment, acquisition,disposal or any other transaction). Any failure to comply with these restrictions may constitute a violationof applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press
release, “Takeda” is sometimes used for convenience where references are made to Takeda and its
subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries ingeneral or to those who work for them. These expressions are also used where no useful purpose is served
by identifying the particular company or companies.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain This press
release and any materials distributed in connection with this press release may contain forward-looking
statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations,including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements
often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”,“intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” orsimilar expressions or the negative thereof. These forward-looking statements are based on assumptions
about many important factors, including the following, which could cause actual results to differ materiallyfrom those expressed or implied by the forward-looking statements: the economic circumstances
surrounding Takeda’s global business, including general economic conditions in Japan and the UnitedStates; competitive pressures and developments; changes to applicable laws and regulations, including
global health care reforms; challenges inherent in new product development, including uncertainty of clinicalsuccess and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for
new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange
rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; theimpact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers,3

including foreign governments in countries in which Takeda operates, or on other facets of its business; thetiming and impact of post-merger integration efforts with acquired companies; the ability to divest assetsthat are not core to Takeda’s operations and the timing of any such divestment(s); and other factors
identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with theU.S.
Securities
andExchange
Commission,
availableon
Takeda’s
websiteat:https://www.takeda.com/investors/ reports/sec-filings/ or at www.sec.gov. Takeda does not undertake toupdate any of the forward-looking statements contained in this press release or any other forward-looking
statements it may make, except as required by law or stock exchange rule. Past performance is not anindicator of future results and the results or statements of Takeda in this press release may not be indicativeof, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
###4